Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

APRE

Aprea Therapeutics Inc

Oct 31 • 04:00PM ET

3.91

Dollar change -0.10
Percentage change -2.49	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD VRTX AMGN BIIB REGN NBIX INCY

| Held by: VTI VXF DFAT DFAC

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	12.57%	Shs Outstand	5.43M	Perf Week	0.26%
Market Cap	21.24M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	5.59%	Shs Float	4.75M	Perf Month	44.55%
Income	-12.93M	PEG	-	EPS next Q	-0.72	Inst Own	42.55%	Short Float	0.32%	Perf Quarter	3.99%
Sales	1.28M	P/S	16.59	EPS this Y	30.55%	Inst Trans	77.00%	Short Ratio	0.69	Perf Half Y	-28.26%
Book/sh	4.71	P/B	0.83	EPS next Y	44.01%	ROA	-44.09%	Short Interest	0.02M	Perf Year	10.51%
Cash/sh	5.28	P/C	0.74	EPS next 5Y	-	ROE	-50.11%	52W Range	2.15 - 8.85	Perf YTD	-16.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.41%	ROI	-48.11%	52W High	-55.80%	Beta	1.03
Dividend TTM	-	Quick Ratio	9.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	81.85%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	9.55	EPS Y/Y TTM	86.77%	Oper. Margin	-1112.69%	RSI (14)	57.66	Volatility	7.67% 12.48%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	410.91%	Profit Margin	-1013.41%	Recom	1.00	Target Price	15.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	33.09%	Payout	-	Rel Volume	0.64	Prev Close	4.01
Sales Surprise	1023.20%	EPS Surprise	5.89%	Sales Q/Q	124.91%	Earnings	Aug 12 BMO	Avg Volume	22.07K	Price	3.91
SMA20	11.25%	SMA50	18.46%	SMA200	-17.49%	Trades		Volume	14,201	Change	-2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy	$37
Sep-29-20	Resumed	JP Morgan	Neutral	$25
Jun-22-20	Initiated	H.C. Wainwright	Neutral	$30
Apr-21-20	Initiated	Robert W. Baird	Outperform	$45
Oct-28-19	Initiated	RBC Capital Mkts	Outperform	$33
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight	$23
Oct-28-19	Initiated	JP Morgan	Neutral	$23

Oct-24-24 08:40AM	Aprea Therapeutics presents preliminary results on APR-1051 (TipRanks)
Oct-23-24 08:30AM	Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire) -6.70%
Oct-14-24 08:30AM	Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-10-24 07:03PM	Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc (GuruFocus.com)
08:30AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire)
08:30AM	Loading…
Oct-09-24 08:30AM	Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development (GlobeNewswire)
Sep-25-24 08:00AM	Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +7.19%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-12-24 08:30AM	Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 (GlobeNewswire) +6.21%
Sep-09-24 05:15PM	UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:30AM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 09:45AM	Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-21-24 08:00AM	Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 (GlobeNewswire)
Jun-17-24 08:30AM	Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 (GlobeNewswire)
May-28-24 08:45AM	Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial (GlobeNewswire)
May-14-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.37%
08:30AM	Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-13-24 04:01PM	Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 09:15AM	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-24 12:00PM	Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire)
Mar-26-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:45AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-24 08:30AM	Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million (GlobeNewswire) -5.05%
08:29AM	Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers (GlobeNewswire)
Mar-05-24 04:45PM	Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-06-24 08:01AM	Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor (GlobeNewswire) +11.97%
08:00AM	Loading…
Jan-30-24 08:00AM	Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 (GlobeNewswire)
Jan-04-24 04:05PM	Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 (GlobeNewswire)
Nov-09-23 04:05PM	Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -5.19%
Oct-24-23 08:00AM	Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways (GlobeNewswire)
Oct-16-23 08:30AM	Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio (GlobeNewswire)
Sep-19-23 08:00AM	Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-11-23 08:00AM	Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors (GlobeNewswire)
Sep-06-23 04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 07:30AM	Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman (GlobeNewswire)
Aug-10-23 07:30AM	Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Jun-14-23 08:00AM	Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference (GlobeNewswire)
May-30-23 08:30AM	Aprea Therapeutics to Present at BIO International Convention (GlobeNewswire) +11.76%
May-15-23 04:05PM	Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM	Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors (GlobeNewswire)
Apr-24-23 09:55AM	Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now (Zacks)
Apr-04-23 12:00PM	All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy (Zacks) -5.01%
Mar-30-23 04:05PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Mar-16-23 08:00AM	Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.26%
Mar-01-23 04:05PM	Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-27-23 04:05PM	Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-22-23 08:41PM	Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.97%
04:05PM	Aprea Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-15-23 08:00AM	Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) (GlobeNewswire)
Feb-13-23 07:00AM	Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split (GlobeNewswire)
Jan-30-23 08:00AM	Aprea Therapeutics Appoints John Hamill as Chief Financial Officer (GlobeNewswire)
Jan-19-23 08:00AM	Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit (GlobeNewswire) -7.57%
Jan-12-23 09:56AM	Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies (Zacks)
Jan-11-23 08:00AM	Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +11.99%
Nov-09-22 04:15PM	Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire) -10.88%
Sep-22-22 06:00PM	Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series (GlobeNewswire) -7.14%
Sep-08-22 08:00AM	Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:15PM	Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Aug-02-22 08:00AM	Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
May-19-22 06:30AM	The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal (American City Business Journals)
May-16-22 09:21AM	Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results (GlobeNewswire) -19.09%
Mar-15-22 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) +5.45% +14.37%
Mar-02-22 04:41AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-14-22 10:00AM	Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-06-22 08:00AM	Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 (GlobeNewswire)
Dec-14-21 08:00AM	Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.05%
Dec-13-21 08:00AM	Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.85%
Dec-10-21 10:30AM	Aprea (APRE) Reports FDA Removal of Clinical Hold on Study (Zacks)
Dec-09-21 12:30PM	FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies (Benzinga)
08:00AM	Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies (GlobeNewswire)
Nov-08-21 04:15PM	Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Nov-04-21 04:15PM	Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting (GlobeNewswire)
Sep-21-21 08:39AM	Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO (Benzinga)
07:01AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Sep-20-21 04:15PM	Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
08:42AM	Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock? (Zacks)
Sep-14-21 08:00AM	Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
Sep-03-21 07:21AM	Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares? (Simply Wall St.)
Aug-12-21 04:15PM	Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) -9.65%
06:00AM	Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program (GlobeNewswire)
Aug-05-21 05:00PM	Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs (GlobeNewswire)
Jul-21-21 08:00AM	Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML (GlobeNewswire) -5.52%
Jun-18-21 08:34AM	Implied Volatility Surging for Aprea (APRE) Stock Options (Zacks)
Jun-17-21 09:19AM	Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal (Zacks) -6.32%
Jun-16-21 09:24AM	Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients (Benzinga) +10.93%
08:00AM	Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint (GlobeNewswire)
Jun-13-21 12:45PM	Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy? (Insider Monkey)
Jun-04-21 01:47AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth? (Simply Wall St.)
May-21-21 06:00AM	Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-18-21 06:00AM	Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-06-21 04:15PM	Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Apr-16-21 09:15AM	Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 (GlobeNewswire) +7.64%
Apr-08-21 11:15AM	Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +13.64%
Mar-16-21 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Feb-16-21 08:04AM	Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions? (Simply Wall St.)

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duey Marc	Director	Oct 18 '24	Sale	4.58	6,462	29,583	233,651	Oct 25 05:42 PM
Gilad Oren	President/CEO	Oct 23 '24	Buy	3.92	500	1,958	333,395	Oct 24 08:30 AM
Duey Marc	Director	Oct 16 '24	Buy	4.39	30,000	131,700	240,113	Oct 17 08:30 AM
Gilad Oren	President/CEO	Oct 15 '24	Buy	2.90	250	725	332,895	Oct 16 08:31 AM
Duey Marc	Director	Oct 14 '24	Buy	2.58	190	490	210,113	Oct 16 08:30 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 11 '24	Buy	2.46	50	123	19,368	Oct 16 08:30 AM
Seizinger Bernd R.	Director	Oct 11 '24	Buy	2.68	10,000	26,800	44,730	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 14 '24	Buy	2.59	1,000	2,590	332,645	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 10 '24	Buy	2.54	150	381	331,645	Oct 15 08:31 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 10 '24	Buy	2.61	450	1,174	19,318	Oct 15 08:30 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Mar 13 '24	Buy	7.29	1,010	7,363	15,503	Mar 14 08:54 PM
Seizinger Bernd R.	Director	Mar 13 '24	Buy	7.29	6,860	50,009	33,685	Mar 14 08:53 PM
HENNEMAN JOHN B III	Director	Mar 13 '24	Buy	7.29	6,860	50,009	8,139	Mar 14 08:52 PM
Gilad Oren	President, CEO	Mar 13 '24	Buy	7.29	2,000	14,580	324,770	Mar 14 08:51 PM

Open in Screener

APTO

Aptose Biosciences Inc

Oct 31 • 04:00PM ET

0.3807

Dollar change -0.0093
Percentage change -2.38	%

Healthcare • Biotechnology • Canada • NASD

APTO Aptose Biosciences Inc daily Stock Chart

Peers: ARGX BCRX AGEN FATE CARA AFMD BLUE DTIL GRTS CRBP

Index	-	P/E	-	EPS (ttm)	-4.43	Insider Own	17.07%	Shs Outstand	18.11M	Perf Week	-1.12%
Market Cap	9.72M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.02M	Perf Month	-5.74%
Income	-40.29M	PEG	-	EPS next Q	-	Inst Own	14.95%	Short Float	1.28%	Perf Quarter	-22.15%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.36	Perf Half Y	-68.01%
Book/sh	-0.12	P/B	-	EPS next Y	-	ROA	-214.76%	Short Interest	0.19M	Perf Year	-86.35%
Cash/sh	0.33	P/C	1.17	EPS next 5Y	-	ROE	-694.13%	52W Range	0.33 - 3.32	Perf YTD	-85.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.18%	ROI	-	52W High	-88.53%	Beta	1.25
Dividend TTM	-	Quick Ratio	0.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.36%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.80	EPS Y/Y TTM	42.38%	Oper. Margin	0.00%	RSI (14)	47.71	Volatility	7.48% 7.25%
Employees	35	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	80.90%	Payout	-	Rel Volume	0.13	Prev Close	0.39
Sales Surprise	-	EPS Surprise	25.86%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	534.42K	Price	0.38
SMA20	1.31%	SMA50	-1.16%	SMA200	-62.60%	Trades		Volume	68,902	Change	-2.38%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-19-20	Initiated	Cantor Fitzgerald	Overweight	$10
Sep-22-20	Initiated	Alliance Global Partners	Buy	$12
Feb-20-20	Initiated	Maxim Group	Buy	$16
Feb-06-20	Reiterated	H.C. Wainwright	Buy	$6 → $9
Jan-09-20	Initiated	Piper Sandler	Overweight	$10
Mar-01-19	Initiated	RBC Capital Mkts	Outperform	$6
Nov-16-18	Initiated	B. Riley FBR	Buy	$5
Dec-13-17	Reiterated	H.C. Wainwright	Buy
Oct-23-17	Resumed	ROTH Capital	Buy	$5
Sep-07-17	Upgrade	H.C. Wainwright	Neutral → Buy	$1 → $4
Jun-08-17	Initiated	Rodman & Renshaw	Neutral	$1

Show Previous Ratings

Sep-05-24 04:15PM	Aptose Announces Results from Special Meeting of Shareholders (GlobeNewswire)
Sep-02-24 04:12AM	Aptose Biosciences secures funds for AML treatment development (Pharmaceutical Technology)
Aug-30-24 04:30PM	Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib (GlobeNewswire)
Aug-15-24 04:30PM	Aptose Announces Adjournment of its Special Meeting of Shareholders (GlobeNewswire)
Aug-08-24 06:07PM	Aptose Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +11.22% -7.53%
05:06PM	Loading…
05:06PM	Aptose Reports Results for the Second Quarter 2024 (GlobeNewswire)
Aug-01-24 07:00AM	NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer (GlobeNewswire) -7.71%
Jul-19-24 05:00PM	Aptose Announces Receipt of Deficiency Notice from Nasdaq (GlobeNewswire) -6.15%
Jun-18-24 05:30PM	Aptose Announces Results from Annual and Special Meeting of Shareholders (GlobeNewswire)
Jun-14-24 07:30AM	Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress (GlobeNewswire)
Jun-13-24 12:00PM	Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jun-03-24 04:30PM	Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-31-24 08:00AM	Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.95%
May-14-24 09:54PM	APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:32PM	Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses (MT Newswires)
04:21PM	Loading…
04:21PM	Aptose Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aptose Reports Results for the First Quarter 2024 (GlobeNewswire)
May-06-24 04:30PM	Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 (GlobeNewswire)
Apr-05-24 12:00PM	What Makes Aptose Biosciences (APTO) a New Buy Stock (Zacks)
Mar-27-24 08:26AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.25%
Mar-26-24 08:53PM	APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023 (InvestorPlace) +5.96%
04:01PM	Aptose Reports Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-18-24 04:30PM	Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 (GlobeNewswire)
Jan-31-24 04:01PM	Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Jan-26-24 08:36AM	Why Is Aptose Biosciences (APTO) Stock Down Today? (InvestorPlace)
08:00AM	Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical (GlobeNewswire)
Dec-09-23 06:30PM	Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting (GlobeNewswire)
Nov-30-23 04:59PM	Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role (GlobeNewswire) -9.29% +9.02%
Nov-10-23 11:21AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript (Insider Monkey) -24.38%
Nov-09-23 04:17PM	Aptose Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.88%
04:00PM	Loading…
04:00PM	Aptose Reports Results for the Third Quarter 2023 (GlobeNewswire)
Nov-02-23 09:00AM	Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting (GlobeNewswire)
Oct-30-23 09:15AM	Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib (GlobeNewswire) -13.52%
Oct-26-23 07:11AM	Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 (GlobeNewswire) +9.30%
Oct-23-23 07:30AM	Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th (GlobeNewswire)
Oct-16-23 07:30AM	Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference (GlobeNewswire) +30.84%
Sep-18-23 07:45AM	Aptose to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +5.17%
Sep-06-23 07:45AM	Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical (GlobeNewswire) -6.19%
Aug-24-23 07:30AM	Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:08PM	Aptose Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +8.75%
04:02PM	Aptose Reports Results for the Second Quarter 2023 (GlobeNewswire)
Jul-27-23 04:04PM	Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023 (GlobeNewswire)
Jun-26-23 04:05PM	Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance (GlobeNewswire) -5.99%
Jun-10-23 12:00PM	Aptose Presents Highlights from Clinical Update (GlobeNewswire)
Jun-05-23 07:30AM	Aptose Biosciences Provides Update on Reverse Stock Split (GlobeNewswire)
May-31-23 07:30AM	Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023 (GlobeNewswire)
May-25-23 04:14PM	Aptose Enters into $25 Million Committed Equity Facility (GlobeNewswire) -6.37%
May-23-23 05:30PM	Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire) -7.98%
May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-11-23 07:28AM	Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability (Simply Wall St.)
May-08-23 04:13PM	Aptose Biosciences: Q1 Earnings Snapshot (AP Finance)
04:01PM	Aptose Reports Results for the First Quarter 2023 (GlobeNewswire)
May-04-23 07:01AM	Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire)
Apr-24-23 07:01AM	Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023 (GlobeNewswire)
Apr-10-23 04:01PM	Aptose to Participate in Canaccord Genuitys 2023 Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-28-23 04:01PM	Aptose Biosciences to Participate in Cantors The Future of Oncology Virtual Symposium (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Annovis Bio (ANVS) This Year? (Zacks)
Mar-27-23 08:45AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 04:44PM	Aptose Reports Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire) +12.98%
Mar-10-23 06:44PM	Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank (GlobeNewswire) -5.33%
Mar-09-23 04:05PM	Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023 (GlobeNewswire)
Mar-02-23 07:30AM	Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Jan-30-23 07:00AM	Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Dec-30-22 08:02AM	We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully (Simply Wall St.) +7.61%
Dec-28-22 07:30AM	Aptose Biosciences to Present at Biotech Showcase 2023 Conference (GlobeNewswire) +7.77%
Dec-12-22 06:15AM	Aptose Biosciences Establishes New At-The-Market Facility (GlobeNewswire)
Dec-11-22 09:00AM	Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations (GlobeNewswire)
Dec-07-22 04:05PM	Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th (GlobeNewswire)
Nov-14-22 07:30AM	Aptose Treats First Patient with Continuous Dosing of New G3 Formulation of Luxeptinib (GlobeNewswire)
Nov-03-22 09:10AM	Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting (GlobeNewswire) +30.55%
Nov-01-22 04:01PM	Aptose Reports Results for the Third Quarter 2022 (GlobeNewswire) +8.32% +10.26%
Oct-18-22 04:01PM	Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022 (GlobeNewswire) -6.03%
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks)
Sep-28-22 01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks) +6.45%
Sep-27-22 11:44AM	Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223 (Zacks)
10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks)
Sep-20-22 09:49AM	Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication (Zacks)
Sep-19-22 12:28PM	Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe (Zacks)
Sep-14-22 07:30AM	Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks)
08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks)
07:30AM	Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D. (GlobeNewswire)
Sep-12-22 07:30AM	Aptoses New G3 Formulation of Luxeptinib Boosts Bioavailability (GlobeNewswire)
Aug-30-22 07:30AM	Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-02-22 04:01PM	Aptose Reports Results for the Second Quarter 2022 (GlobeNewswire) +8.46%
Jul-27-22 07:30AM	Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Jul-23-22 08:08AM	Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-19-22 04:01PM	Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022 (GlobeNewswire)
Jun-27-22 07:30AM	Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer (GlobeNewswire)
Jun-02-22 08:10PM	CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event (GlobeNewswire) -5.52%
05:30PM	Aptose Presents Highlights from Corporate Update and KOL Event (GlobeNewswire)
May-31-22 04:15PM	Aptose Biosciences Announces Results of Annual Meeting of Shareholders (GlobeNewswire) +5.96%
May-25-22 08:30AM	Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd (GlobeNewswire)
May-12-22 10:00AM	Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd (GlobeNewswire) +6.22%
May-09-22 04:01PM	Aptose Reports Results for the First Quarter 2022 (GlobeNewswire)
May-04-22 07:30AM	Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation (GlobeNewswire)
May-03-22 07:30AM	Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-22 04:10PM	Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation (GlobeNewswire)

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

APRE

Aprea Therapeutics Inc

APTO

Aptose Biosciences Inc

Upgrade your FINVIZ experience